

CLINICAL CANCER RESEARCH

TABLE OF CONTENTS

HIGHLIGHTS

1779 Selected Articles from This Issue

SPECIAL FEATURES

CCR Translations

1781 Propranolol: What is BLOCKing Its Clinical Investigation in Breast Cancer?
Anne H. Blaes, Evidio Domingo-Musibay, and Kevin Kalinsky

See related article, p. 1803

1784 Double Trouble: Concomitant *RB1* and *BRCA2* Depletion Evokes Aggressive Phenotypes
Amy C. Mandigo and Karen E. Knudsen

See related article, p. 2047

Review

1787 Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models
René Bruno, Dean Bottino, Dinesh P. de Alwis, Antonio T. Fojo, Jérémie Guedj, Chao Liu, Kristin R. Swanson, Jenny Zheng, Yanan Zheng, and Jin Y. Jin

RESEARCH BRIEFS: CLINICAL TRIAL BRIEF REPORT

1796 A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers
Paul K. Paik, Rachel K. Kim, Linda Ahn, Andrew J. Plodkowski, Ai Ni, Mark T.A. Donoghue, Philip Jonsson, Miguel Villalona-Calero, Kenneth Ng, Daniel McFarland, John J. Fiore, Afsheen Iqbal, Juliana Eng, Mark G. Kris, and Charles M. Rudin

CLINICAL TRIALS: TARGETED THERAPY

1803 Preoperative β -Blockade with Propranolol Reduces Biomarkers of Metastasis in Breast Cancer: A Phase II Randomized Trial

Jonathan G. Hiller, Steven W. Cole, Elizabeth M. Crone, David J. Byrne, David M. Shackelford, Jia-Min B. Pang, Michael A. Henderson, Sophie S. Nightingale, Kwok M. Ho, Paul S. Myles, Stephen Fox, Bernhard Riedel, and Erica K. Sloan

See related commentary, p. 1781

1812 Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)

Douglas B. Johnson, Fengmin Zhao, Marcus Noel, Gregory J. Riely, Edith P. Mitchell, John J. Wright, Helen X. Chen, Robert J. Gray, Shuli Li, Lisa M. McShane, Larry V. Rubinstein, David Patton, P. Mickey Williams, Stanly R. Hamilton, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, and Keith T. Flaherty

1820 First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma

Patrick Y. Wen, Timothy F. Cloughesy, Alan G. Olivero, Kari M. Morrissey, Timothy R. Wilson, Xuyang Lu, Lars U. Mueller, Alexandre F. Coimbra, Benjamin M. Ellingson, Elizabeth Gerstner, Eudocia Q. Lee, and Jordi Rodon

1829 A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma

Anusha Kalbasi, Mitchell Kamrava, Fang-I Chu, Donatello Telesca, Ritchell Van Dams, Yingli Yang, Dan Ruan, Scott D. Nelson, Sarah M. Dry, Jackie Hernandez, Bartosz Chmielowski, Arun S. Singh, Susan V. Bukata, Nicholas M. Bernthal, Michael L. Steinberg, Joanne B. Weidhaas, and Fritz C. Eilber

TABLE OF CONTENTS

1837 Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study

Margaret von Mehren, Suzanne George, Michael C. Heinrich, Scott M. Schuetze, Jeffrey T. Yap, Jain Q. Yu, Amanda Abbott, Samuel Litwin, John Crowley, Martin Belinsky, Katherine A. Janeway, Jason L. Hornick, Douglas B. Flieder, Rashmi Chugh, Lori Rink, and Annick D. Van den Abbeele

CLINICAL TRIALS: IMMUNOTHERAPY

1846 Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria

A C Ignacio Matos, Juan Martin-Liberal, Alonso García-Ruiz, Cinta Hierro, Maria Ochoa de Olza, Cristina Viaplana, Analia Azaro, Maria Vieito, Irene Braña, Gemma Mur, Javier Ros, Jose Mateos, Guillermo Villacampa, Roger Berché, Mafalda Oliveira, Maria Alsina, Elena Elez, Ana Oaknin, Eva Muñoz-Couselo, Joan Carles, Enriqueta Felip, Jordi Rodón, Josep Taberner, Rodrigo Dienstmann, Raquel Perez-Lopez, and Elena Garralda

PRECISION MEDICINE AND IMAGING

1856 Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial

Daniel Rodriguez Gutierrez, Chris Jones, Pascale Varlet, Alan Mackay, Daniel Warren, Monika Warmuth-Metz, Esther Sánchez Aliaga, Raphael Calmon, Darren R. Hargrave, Adela Cañete, Maura Massimino, Amedeo A. Azizi, Marie-Cécile Le Deley, Frank Saran, Raphael F. Rousseau, Gudrun Zahlmann, Josep Garcia, Gilles Vassal, Jacques Grill, Paul S. Morgan, and Tim Jaspan

1866 Radiogenomic-Based Survival Risk Stratification of Tumor Habitat on Gd-T1w MRI Is Associated with Biological Processes in Glioblastoma

Niha Beig, Kaustav Bera, Prateek Prasanna, Jacob Antunes, Ramon Correa, Salendra Singh, Anas Saeed Bamashmos, Marwa Ismail, Nathaniel Braman, Ruchika Verma, Virginia B. Hill, Volodymyr Statsevych, Manmeet S. Ahluwalia, Vinay Varadan, Anant Madabhushi, and Pallavi Tiwari

1877 Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers

A C Aparna R. Parikh, Amikasma Mojtahed, Jaime L. Schneider, Katie Kanter, Emily E. Van Seventer, Isobel J. Fetter, Ashraf Thabet, Madeleine G. Fish, Bezaye Teshome, Kathryn Fosbenner, Brandon Nadres, Heather A. Shahzade, Jill N. Allen, Lawrence S. Blaszkowsky, David P. Ryan, Bruce Giantonio, Lipika Goyal, Ryan D. Nipp, Eric Roeland, Colin D. Weekes, Jennifer Y. Wo, Andrew X. Zhu, Dora Dias-Santagata, A. John Iafrate, Jochen K. Lennerz, Theodore S. Hong, Giulia Siravegna, Nora Horick, Jeffrey W. Clark, and Ryan B. Corcoran

1886 Circulating Tumor Cells and Early Relapse in Node-positive Melanoma

Anthony Lucci, Carolyn S. Hall, Sapna P. Patel, Boomadevi Narendran, Jessica B. Bauldry, Richard E. Royal, Mandar Karhade, Joshua R. Upshaw, Jennifer A. Wargo, Isabella C. Glitza, Michael K.K. Wong, Rodabe N. Amaria, Hussein A. Tawbi, Adi Diab, Michael A. Davies, Jeffrey E. Gershenwald, Jeffrey E. Lee, Patrick Hwu, and Merrick I. Ross

1896 A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial

Thomas Karn, Tobias Meissner, Karsten E. Weber, Christine Solbach, Carsten Denkert, Knut Engels, Peter A. Fasching, Bruno V. Sinn, Iris Schrader, Jan Budczies, Frederik Marmé, Volkmar Müller, Uwe Holtrich, Bernd Gerber, Christian Schem, Brandon M. Young, Claus Hanusch, Elmar Stickeler, Jens Huober, Marion van Mackelenbergh, Brian Leyland-Jones, Tanja Fehm, Valentina Nekljudova, Michael Untch, and Sibylle Loibl

1905 Racial Differences in the Association Between Luminal Master Regulator Gene Expression Levels and Breast Cancer Survival

A C Jung S. Byun, Sandeep K. Singhal, Samson Park, Dae Ik Yi, Tingfen Yan, Ambar Caban, Alana Jones, Partha Mukhopadhyay, Sara M. Gil, Stephen M. Hewitt, Lisa Newman, Melissa B. Davis, Brittany D. Jenkins, Jorge L. Sepulveda, Adriana De Siervi, Anna María Nápoles, Nasreen A. Vohra, and Kevin Gardner

1915 Computationally Derived Image Signature of Stromal Morphology Is Prognostic of Prostate Cancer Recurrence Following Prostatectomy in African American Patients

Hersh K. Bhargava, Patrick Leo, Robin Elliott, Andrew Janowczyk, Jon Whitney, Sanjay Gupta, Pingfu Fu, Kosj Yamoah, Francesca Khani, Brian D. Robinson, Timothy R. Rebbeck, Michael Feldman, Priti Lal, and Anant Madabhushi

TABLE OF CONTENTS

- 1924** **Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer**
Seyed Pairawan, Kenneth R. Hess, Filip Janku, Nora S. Sanchez, Kenna R. Mills Shaw, Cathy Eng, Senthilkumar Damodaran, Milind Javle, Ahmed O. Kaseb, David S. Hong, Vivek Subbiah, Siqing Fu, David R. Fogelman, Victoria M. Raymond, Richard B. Lanman, and Funda Meric-Bernstam
- 1932** **Metabolic Imaging Using Hyperpolarized Pyruvate-Lactate Exchange Assesses Response or Resistance to the EGFR Inhibitor Cetuximab in Patient-Derived HNSCC Xenografts**
A C Lionel Mignon, Stefania Acciardo, Florian Gourgue, Nicolas Joudiou, Xavier Caignet, Rose-Marie Goebbels, Cyril Corbet, Olivier Feron, Caroline Bouzin, Patrice D. Cani, Jean-Pascal Machiels, Sandra Schmitz, and Bénédicte F. Jordan
- 1944** **Deep Learning to Distinguish Benign from Malignant Renal Lesions Based on Routine MR Imaging**
Ianto Lin Xi, Yijun Zhao, Robin Wang, Marcello Chang, Subhanik Purkayastha, Ken Chang, Raymond Y. Huang, Alvin C. Silva, Martin Vallières, Peiman Habibollahi, Yong Fan, Beiji Zou, Terence P. Gade, Paul J. Zhang, Michael C. Soulen, Zishu Zhang, Harrison X. Bai, and S. William Stavropoulos
- 1977** **Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome**
Ryan L. Powles, Vikram B. Wali, Xiaotong Li, William E. Barlow, Zeina Nahleh, Alastair M. Thompson, Andrew K. Godwin, Christos Hatzis, and Lajos Pusztai
- 1985** **Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer**
A C Stefanie Hammer, Urs B. Hagemann, Sabine Zitzmann-Kolbe, Aasmund Larsen, Christine Ellingsen, Solene Geraudie, Derek Grant, Baard Indrevoll, Roger Smeets, Oliver von Ahnen, Alexander Kristian, Pascale Lejeune, Hartwig Hennekes, Jenny Karlsson, Roger M. Bjerke, Olav B. Ryan, Alan S. Cuthbertson, and Dominik Mumberg
- 1997** **A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer**
Joan M. Romero, Barbara Grünwald, Gun-Ho Jang, Prashant P. Bavi, Aaditeya Jhaveri, Mehdi Masoomian, Sandra E. Fischer, Amy Zhang, Robert E. Denroche, Ilinca M. Lungu, Angela De Luca, John M.S. Bartlett, Jing Xu, Niandong Li, Sharon Dhaliwal, Sheng-Ben Liang, Dianne Chadwick, Foram Vyas, Peter Bronsert, Rama Khokha, Tracy L. McGaha, Faiyaz Notta, Pamela S. Ohashi, Susan J. Done, Grainne M. O'Kane, Julie M. Wilson, Jennifer J. Knox, Ashton Connor, Yifan Wang, George Zogopoulos, and Steven Gallinger
- 2011** **Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors**
Aaron T. Scott, Michelle Weitz, Patrick J. Breheny, Po Hien Ear, Benjamin Darbro, Bart J. Brown, Terry A. Braun, Guiying Li, Shaikamjad Umesalma, Courtney A. Kaemmer, Chandra K. Maharjan, Dawn E. Quelle, Andrew M. Bellizzi, Chandrikha Chandrasekharan, Joseph S. Dillon, Thomas M. O'Dorisio, and James R. Howe
- 2022** **A Combinatorial Strategy for Targeting BRAF^{V600E}-Mutant Cancers with BRAF^{V600E} Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib)**
A C Chandrayee Ghosh, Suresh Kumar, Yevgeniya Kushchayeva, Kelli Gaskins, Myriem Boufraqueh, Darmood Wei, Sudheer Kumar Gara, Lisa Zhang, Ya-qin Zhang, Min Shen, Sanjit Mukherjee, and Electron Kebebew
- 1953** **CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies**
A C Steven N. Quayle, Natasha Girgis, Dharma R. Thapa, Zohra Merazga, Melissa M. Kemp, Alex Histed, Fan Zhao, Miguel Moreta, Paige Ruthardt, Sandrine Hulot, Alyssa Nelson, Lauren D. Kraemer, Dominic R. Beal, Luke Witt, Jessica Ryabin, Jonathan Soriano, Mark Haydock, Emily Spaulding, John F. Ross, Peter A. Kiener, Steven Almo, Rodolfo Chaparro, Ronald Seidel, Anish Suri, Saso Cemerski, Kenneth J. Pienta, and Mary Ellen Simcox
- 1965** **Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer**
Yingming Li, Rendong Yang, Christine M. Henzler, Yeung Ho, Courtney Passow, Benjamin Auch, Suzanne Carreira, Daniel Nava Rodrigues, Claudia Bertan, Tae Hyun Hwang, David A. Quigley, Ha X. Dang, Colm Morrissey, Michael Fraser, Stephen R. Plymate, Christopher A. Maher, Felix Y. Feng, Johann S. de Bono, and Scott M. Dehm

TRANSLATIONAL CANCER MECHANISMS AND THERAPY

TABLE OF CONTENTS

2037 Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in *EGFR* Mutation-Positive Non-Small Cell Lung Cancer

Kohsuke Isomoto, Koji Haratani, Hidetoshi Hayashi, Shigeki Shimizu, Shuta Tomida, Takashi Niwa, Toshihide Yokoyama, Yasushi Fukuda, Yasutaka Chiba, Ryoji Kato, Junko Tanizaki, Kaoru Tanaka, Masayuki Takeda, Takashi Ogura, Tadashi Ishida, Akihiko Ito, and Kazuhiko Nakagawa

2047 Significance of *BRCA2* and *RB1* Co-loss in Aggressive Prostate Cancer Progression

Goutam Chakraborty, Joshua Armenia, Ying Z. Mazzu, Subhiksha Nandakumar, Konrad H. Stopsack, Mohammad O. Atiq, Kazumasa Komura, Lina Jehane, Rahim Hirani, Kalyani Chadalavada, Yuki Yoshikawa, Nabeela A. Khan, Yu Chen, Wassim Abida, Lorelei A. Mucci, Gwo-Shu Mary Lee, Gouri J. Nanjangud, and Philip W. Kantoff

See related commentary, p. 1784

2065 *Kdm6a* Deficiency Activates Inflammatory Pathways, Promotes M2 Macrophage Polarization, and Causes Bladder Cancer in Cooperation with *p53* Dysfunction


Kohei Kobatake, Ken-ichiro Ikeda, Yuichiro Nakata, Norimasa Yamasaki, Takeshi Ueda, Akinori Kanai, Kazuhiro Sentani, Yasuyuki Sera, Tetsutaro Hayashi, Miho Koizumi, Yoshihiko Miyakawa, Toshiya Inaba, Yusuke Sotomaru, Osamu Kaminuma, Tatsuo Ichinohe, Zen-ichiro Honda, Wataru Yasui, Shigeo Horie, Peter C. Black, Akio Matsubara, and Hiroaki Honda

AC AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows a section of primary tumor from a patient with breast cancer who was treated with the beta-blocker propranolol. Immunohistochemical staining shows infiltration by CD8-positive T cells. For details, see the article by Hiller and colleagues on page 1803 of this issue.



Clinical Cancer Research

26 (8)

Clin Cancer Res 2020;26:1779-2079.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/26/8>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/26/8>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.